Innate Pharma S.A. (EPA:IPH)
France
· Delayed Price · Currency is EUR 2.010
-0.035 (-1.71%)
May 12, 2025, 5:35 PM CET
Innate Pharma Revenue
In the year 2024, Innate Pharma had annual revenue of 20.12M EUR, down -67.36%. Innate Pharma had revenue of 7.78M in the half year ending December 31, 2024, a decrease of -35.66%.
Revenue
20.12M
Revenue Growth
-67.36%
P/S Ratio
9.21
Revenue / Employee
111.17K
Employees
181
Market Cap
185.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |
Innate Pharma News
- 7 days ago - Innate Pharma announces conference call and webcast for Q1 2025 business update - Business Wire
- 12 days ago - Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F - Business Wire
- 13 days ago - Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting - Business Wire
- 19 days ago - Innate Pharma Announces €15M Investment by Sanofi - Business Wire
- 20 days ago - Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company - Business Wire
- 27 days ago - Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition - Business Wire
- 27 days ago - Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025 - Business Wire
- 5 weeks ago - Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum - Business Wire